IGC Pharma (IGC) Depreciation & Amortization (CF) (2010 - 2025)
IGC Pharma (IGC) posted quarterly Depreciation & Amortization (CF) of $119000.0 for Q3 2025, down 17.93% year-over-year from $145000.0 in Q3 2024, and down 15.6% quarter-over-quarter from $141000.0 in Q2 2025.
IGC Pharma (IGC) Depreciation & Amortization (CF) (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Depreciation & Amortization (CF) for 16 consecutive years, with $119000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Depreciation & Amortization (CF) fell 17.93% year-over-year to $119000.0; the TTM figure through Mar 2026 stood at $260000.0 (down 57.93% YoY), while the FY2026 annual figure was $58000.0, down 90.61% from the prior year.
- Depreciation & Amortization (CF) slipped to $119000.0 in Q3 2025 per IGC's latest filing, from $141000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $172000.0 in Q4 2022 and bottomed at $119000.0 in Q3 2025.
- Historically, Depreciation & Amortization (CF) has averaged $157315.8 across 5 years, with a median of $160000.0 in 2023.
- Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) jumped 121.33% — and 2025, when it fell 17.93%.
- IGC Pharma's Depreciation & Amortization (CF) stood at $166000.0 in 2021, then rose by 3.61% to $172000.0 in 2022, then dropped by 6.98% to $160000.0 in 2023, then declined by 1.88% to $157000.0 in 2024, then retreated by 24.2% to $119000.0 in 2025.
- Business Quant data shows IGC's Depreciation & Amortization (CF) at $119000.0 in Q3 2025, $141000.0 in Q2 2025, and $154000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 119,000.00 |
| Sep 30, 2025 | 119,000.00 |
| Jun 30, 2025 | 141,000.00 |
| Jun 30, 2025 | 141,000.00 |
| Mar 31, 2025 | 154,000.00 |
| Mar 31, 2025 | 154,000.00 |
| Dec 31, 2024 | 157,000.00 |
| Dec 31, 2024 | 157,000.00 |
| Sep 30, 2024 | 145,000.00 |
| Sep 30, 2024 | 145,000.00 |
| Jun 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 162,000.00 |
| Mar 31, 2024 | 164,000.00 |
| Mar 31, 2024 | 164,000.00 |
| Dec 31, 2023 | 160,000.00 |
| Dec 31, 2023 | 160,000.00 |
| Sep 30, 2023 | 158,000.00 |
| Sep 30, 2023 | 158,000.00 |
| Jun 30, 2023 | 155,000.00 |
| Jun 30, 2023 | 155,000.00 |